Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study (ANTHEM-HF)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Cyberonics, Inc.
ClinicalTrials.gov Identifier:
NCT01823887
First received: April 1, 2013
Last updated: February 17, 2015
Last verified: February 2015

April 1, 2013
February 17, 2015
July 2012
April 2014   (final data collection date for primary outcome measure)
  • Cardiac Function [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Left ventricular end-systolic volume (LVESV) and ejection fraction (EF)
  • Adverse Events [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    Incidence of procedure and device-related complications
  • Cardiac Function [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Composite of left ventricular end-systolic volume (LVESV), left ventricular end-systolic diameter (LVESD), and ejection fraction (EF)
  • Adverse Events [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    Incidence of procedure and device-related complications
Complete list of historical versions of study NCT01823887 on ClinicalTrials.gov Archive Site
  • Functional Status [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    6-minute walk test
  • Quality of Life [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Minnesota Living with Heart Failure Questionnaire
  • Functional Status [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    New York Heart Association Class
  • Autonomic Function [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Heart Rate Variability (HRV)
  • Blood Biomarkers [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Blood Levels of Heart Failure Biomarkers
  • Cardiac Function [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Left ventricular end-systolic diameter (LVESD)
  • Functional Status [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    6-minute walk test
  • Quality of Life [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Minnesota Living with Heart Failure Questionnaire
  • Functional Status [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    New York Heart Association Class
  • Autonomic Function [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Heart Rate Variability (HRV)
  • Blood Biomarkers [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Blood Levels of Heart Failure Biomarkers
Not Provided
Not Provided
 
Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study
Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study
The ANTHEM-HF Study is designed to demonstrate the safety and efficacy of vagus nerve stimulation (VNS) with the Cyberonics VNS Therapy System for the treatment of subjects with symptomatic heart failure.
Heart failure patients will be enrolled and randomized to cervical VNS implantation on either the left side or right side. After a 2-week post-implantation recovery period and a 10-week stimulation titration period, continuous periodic stimulation will be performed for 6 months, with data collection at 3 months and 6 months.
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Congestive Heart Failure
Device: Vagus Nerve Stimulation (VNS)
Electrical Stimulation of the Vagus Nerve
  • Experimental: Left Sided Stimulation
    Left cervical Vagus Nerve Stimulation (VNS)
    Intervention: Device: Vagus Nerve Stimulation (VNS)
  • Experimental: Right Sided Stimulation
    Right Cervical Vagus Nerve Stimulation (VNS)
    Intervention: Device: Vagus Nerve Stimulation (VNS)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
June 2014
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with symptomatic heart failure, New York Heart Association (NYHA) class II/III with reduced EF and dilated hearts
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
India
 
NCT01823887
C-01
Yes
Not Provided
Not Provided
Cyberonics, Inc.
Cyberonics, Inc.
Not Provided
Study Director: Imad Libbus, PhD Cyberonics, Inc.
Cyberonics, Inc.
February 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP